Advantages 

SYNLAB GROUP 

Guaranteed by the experience of the absolute European leader in laboratory diagnostics. 

COMPLETE 

• Validated in two clinical studies that evaluated more than 2,400 postmenopausal women with early-stage breast cancer. 
• Approved by the regulatory agencies of the United States (FDA) and Europe (EMA) as a prognostic tool in early breast cancer; 

• Provides the assessment of recurrence risk over up to 10 years and the intrinsic subtype. 

Extra Information 

DOCUMENTATION – Available on the SYNLAB Direct for clients 

• Informed Consent; 
• Clinical Questionnaire; 
• Medical Request. 

PREPARATION 

• Fasting is not necessary for the exam. 

Additional Information 

The report includes different parameters: 

• Lymph node involvement and Intrinsic subtype – risk classification and information for therapeutic guidelines. 
• ROR– numerical value from 0 to 100 related to the 10-year recurrence risk; 
• Risk classification: Establishes the risk of recurrence in 10 years, classifying into three possible groups: Low risk, intermediate risk, and high risk.